Literature DB >> 23783119

Decoding and unlocking the BCL-2 dependency of cancer cells.

Philippe Juin1, Olivier Geneste, Fabien Gautier, Stéphane Depil, Mario Campone.   

Abstract

Cancer cells are subject to many apoptotic stimuli that would kill them were it not for compensatory prosurvival alterations. BCL-2-like (BCL-2L) proteins contribute to such aberrant behaviour by engaging a network of interactions that is potent at promoting survival but that is also fragile: inhibition of a restricted number of interactions may suffice to trigger cancer cell death. Currently available and novel compounds that inhibit these interactions could be efficient therapeutic agents if this phenotype of BCL-2L dependence was better understood at a molecular, cellular and systems level and if it could be diagnosed by relevant biomarkers.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23783119     DOI： 10.1038/nrc3538

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  125 in total

1.  MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria.

Authors:  Yehudit Zaltsman; Liat Shachnai; Natalie Yivgi-Ohana; Michal Schwarz; Maria Maryanovich; Riekelt H Houtkooper; Frédéric Maxime Vaz; Francesco De Leonardis; Giuseppe Fiermonte; Ferdinando Palmieri; Bernhard Gillissen; Peter T Daniel; Erin Jimenez; Susan Walsh; Carla M Koehler; Soumya Sinha Roy; Ludivine Walter; György Hajnóczky; Atan Gross
Journal:  Nat Cell Biol       Date:  2010-05-02       Impact factor: 28.824

Review 2.  Shedding light on apoptosis at subcellular membranes.

Authors:  Justin Kale; Qian Liu; Brian Leber; David W Andrews
Journal:  Cell       Date:  2012-12-07       Impact factor: 41.582

3.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

4.  Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.

Authors:  Alexander Aranovich; Qian Liu; Tony Collins; Fei Geng; Sudeepa Dixit; Brian Leber; David W Andrews
Journal:  Mol Cell       Date:  2012-03-30       Impact factor: 17.970

5.  Direct and selective small-molecule activation of proapoptotic BAX.

Authors:  Evripidis Gavathiotis; Denis E Reyna; Joseph A Bellairs; Elizaveta S Leshchiner; Loren D Walensky
Journal:  Nat Chem Biol       Date:  2012-05-27       Impact factor: 15.040

6.  Prostaglandins antagonistically control Bax activation during apoptosis.

Authors:  L Lalier; P-F Cartron; C Olivier; C Logé; G Bougras; J-M Robert; L Oliver; F M Vallette
Journal:  Cell Death Differ       Date:  2010-10-22       Impact factor: 15.828

7.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

8.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

9.  N-terminal truncation of antiapoptotic MCL1, but not G2/M-induced phosphorylation, is associated with stabilization and abundant expression in tumor cells.

Authors:  Alfredo De Biasio; Julie A Vrana; Ping Zhou; Liping Qian; Christine K Bieszczad; Karen E Braley; Aaron M Domina; Steven J Weintraub; John M Neveu; William S Lane; Ruth W Craig
Journal:  J Biol Chem       Date:  2007-06-08       Impact factor: 5.157

10.  c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.

Authors:  Mario Campone; Bélinda Noël; Cécile Couriaud; Morgan Grau; Yannis Guillemin; Fabien Gautier; Wilfried Gouraud; Catherine Charbonnel; Loïc Campion; Pascal Jézéquel; Frédérique Braun; Benjamin Barré; Olivier Coqueret; Sophie Barillé-Nion; Philippe Juin
Journal:  Mol Cancer       Date:  2011-09-07       Impact factor: 27.401
View more
  92 in total

Review 1.  Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.

Authors:  D Merino; S W Lok; J E Visvader; G J Lindeman
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

2.  Primary and liver metastasis-derived cell lines from KrasG12D; Trp53R172H; Pdx-1 Cre animals undergo apoptosis in response to triptolide.

Authors:  Veena Sangwan; Sulagna Banerjee; Kelsey M Jensen; Zhiyu Chen; Rohit Chugh; Vikas Dudeja; Selwyn M Vickers; Ashok K Saluja
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

3.  Sphingolipid distribution at mitochondria-associated membranes (MAMs) upon induction of apoptosis.

Authors:  Vincent Mignard; Nolwenn Dubois; Didier Lanoé; Marie-Pierre Joalland; Lisa Oliver; Claire Pecqueur; Dominique Heymann; François Paris; François M Vallette; Lisenn Lalier
Journal:  J Lipid Res       Date:  2020-04-29       Impact factor: 5.922

Review 4.  Mitochondria: gatekeepers of response to chemotherapy.

Authors:  Kristopher A Sarosiek; Triona Ni Chonghaile; Anthony Letai
Journal:  Trends Cell Biol       Date:  2013-09-21       Impact factor: 20.808

5.  Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.

Authors:  Ayano Kabashima; Petra Hirsova; Steven F Bronk; Matthew C Hernandez; Mark J Truty; Sumera Rizvi; Scott H Kaufmann; Gregory J Gores
Journal:  J Hepatol       Date:  2018-03-09       Impact factor: 25.083

6.  BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.

Authors:  Z Xu; P P Sharp; Y Yao; D Segal; C H Ang; S L Khaw; B J Aubrey; J Gong; G L Kelly; M J Herold; A Strasser; A W Roberts; W S Alexander; C J Burns; D C S Huang; S P Glaser
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

7.  Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Authors:  Rongqing Pan; Vivian R Ruvolo; Jun Wei; Marina Konopleva; John C Reed; Maurizio Pellecchia; Michael Andreeff; Peter P Ruvolo
Journal:  Blood       Date:  2015-06-04       Impact factor: 22.113

8.  Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Authors:  Xiaojia Niu; Jianyun Zhao; Jun Ma; Chengzhi Xie; Holly Edwards; Guan Wang; J Timothy Caldwell; Shengyan Xiang; Xiaohong Zhang; Roland Chu; Zhihong J Wang; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

Review 9.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

10.  Pharmacological inhibition of caspase-8 limits lung tumour outgrowth.

Authors:  Michela Terlizzi; Vincenzo Giuseppe Di Crescenzo; Giuseppe Perillo; Antonio Galderisi; Aldo Pinto; Rosalinda Sorrentino
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.